<?xml version="1.0" encoding="utf-8"?><api:response xmlns:api="http://www.symplectic.co.uk/publications/api"><api:version uri="https://mypublications.shef.ac.uk/" elements-version="6.15.0.3976" schema-version="6.13" product-name="myPublications"/><api:request href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/987"/><api:result><api:object category="publication" id="987" last-affected-when="2024-04-14T07:09:33.81+01:00" last-modified-when="2024-04-14T07:09:33.81+01:00" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/987" created-when="2010-05-17T13:47:29.013+01:00" type-id="5" type-display-name="Journal article" type="journal-article"><api:privacy-level>Public</api:privacy-level><api:privacy-level-locked>false</api:privacy-level-locked><api:ever-approved>true</api:ever-approved><api:reporting-date-1>2000-05-01</api:reporting-date-1><api:allow-type-switching>true</api:allow-type-switching><api:records><api:record format="native" id="4208873" source-id="28" source-name="eprints" source-display-name="White Rose Research Online" id-at-source="107826" last-modified-when="2022-12-29T02:07:28.737+00:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>Persistent gestational trophoblastic disease is potentially fatal, but the majority of patients are cured with chemotherapy. Any
developments in treatment are therefore being directed towards maintaining efficacy and reducing toxicity. We evaluated efficacy and toxicity
of methotrexate, etoposide and dactinomycin (MEA) as first-line therapy for high risk disease and etoposide and dactinomycin (EA) as
second-line therapy for methotrexate-refractory low risk disease in a retrospective analysis of 73 patients (38 MEA, 35 EA) treated since 1986
at a supra-regional centre. The median follow-up period was 5.5 years and the median number of cycles received was 7. The overall complete
response rate was 85% (97% for EA, 75% for MEA). Of eight patients who failed to respond, four have since died and four were cured with
platinum-based chemotherapy. Alopecia was universal. Grade II or worse nausea, emesis, or stomatitis was observed in 29%, 30% and 37%
respectively. Fifty-one per cent experienced grade II/III anaemia, 8% grade II or higher thrombocytopenia and 64% grade III or IV neutropenia;
in six cases this was complicated by sepsis. Fifty-four per cent of patients went on to have a normal pregnancy. No patient has developed a
second malignancy. In conclusion, the MEA and EA chemotherapy regimens for persistent trophoblastic disease are very well tolerated, do
not appear to affect future fertility and are associated with excellent, sustained complete response rates.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Dobson</api:last-name><api:initials>LS</api:initials><api:first-names>LS</api:first-names><api:separate-first-names><api:first-name>L</api:first-name><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="18786" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/18786"/></api:links><api:last-name>Hancock</api:last-name><api:initials>BW</api:initials><api:first-names>BW</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1054/bjoc.2000.1176</api:text><api:links><api:link type="doi" href="http://doi.org/10.1054/bjoc.2000.1176"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1054/bjoc.2000.1176"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1532-1827</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0007-0920</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>9</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>British Journal of Cancer</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>gestational trophoblastic disease</api:keyword><api:keyword>combination chemotherapy</api:keyword></api:keywords></api:field><api:field name="notes" type="text" display-name="Other information"><api:text>© 2000 Cancer Research Campaign.  Twelve months after publication in an issue of BJC, all content is made freely available to readers via PubMed Central and the BJC website (www.bjcancer.com) under the terms of BJC’s attribution, non commercial, share alike licence (CC BY NC SA)</api:text></api:field><api:field name="online-publication-date" type="date" display-name="Online publication date"><api:date><api:day>4</api:day><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>1547</api:begin-page><api:end-page>1552</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>5</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="public-url" type="text" display-name="Public URL"><api:text>https://eprints.whiterose.ac.uk/id/eprint/107826</api:text></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Cancer Research UK</api:text></api:field><api:field name="publisher-url" type="text" display-name="Link 2"><api:text>https://doi.org/10.1054/bjoc.2000.1176</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>18</api:day><api:month>11</api:month><api:year>2016</api:year></api:date></api:field><api:field name="record-made-public-at-source-date" type="date" display-name="Record made publicly available"><api:date><api:day>16</api:day><api:month>12</api:month><api:year>2016</api:year></api:date></api:field><api:field name="repository-status" type="text" display-name="Availability"><api:text>Public</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>82</api:text></api:field><api:files><api:file proprietary-id="https://eprints.whiterose.ac.uk/id/file/1360434"><api:filename>Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease.pdf</api:filename><api:file-url>https://eprints.whiterose.ac.uk/107826/1/Persistent gestational trophoblastic disease%3A results of MEA %28methotrexate%2C etoposide and dactinomycin%29 as first-line chemotherapy in high risk disease and EA %28etoposide and dactinomycin%29 as second-line therapy for low risk disease.pdf</api:file-url><api:extension>pdf</api:extension><api:file-size>85130</api:file-size><api:mime-type>application/pdf</api:mime-type><api:checksum algorithm="md5">4B199218CCB6D29E345FFEB50C64BD73</api:checksum><api:file-version>Published version</api:file-version></api:file></api:files></api:native></api:record><api:record format="native" id="1903261" source-id="1" source-name="manual" source-display-name="Manual" id-at-source="F2107B96-9110-42CB-BB1E-6F0C2343B183" last-modified-when="2016-12-16T11:05:00.607+00:00"><api:verification-status>verified</api:verification-status><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>Persistent gestational trophoblastic disease is potentially fatal, but the majority of patients are cured with chemotherapy. Any developments in treatment are therefore being directed towards maintaining efficacy and reducing toxicity. We evaluated efficacy and toxicity of methotrexate, etoposide and dactinomycin (MEA) as first-line therapy for high risk disease and etoposide and dactinomycin (EA) as second-line therapy for methotrexate-refractory low risk disease in a retrospective analysis of 73 patients (38 MEA, 35 EA) treated since 1986 at a supra-regional centre. The median follow-up period was 5.5 years and the median number of cycles received was 7. The overall complete response rate was 85% (97% for EA, 75% for MEA). Of eight patients who failed to respond, four have since died and four were cured with platinum-based chemotherapy. Alopecia was universal. Grade II or worse nausea, emesis, or stomatitis was observed in 29%, 30% and 37% respectively. Fifty-one per cent experienced grade II/III anaemia, 8% grade II or higher thrombocytopenia and 64% grade III or IV neutropenia; in six cases this was complicated by sepsis. Fifty-four per cent of patients went on to have a normal pregnancy. No patient has developed a second malignancy. In conclusion, the MEA and EA chemotherapy regimens for persistent trophoblastic disease are very well tolerated, do not appear to affect future fertility and are associated with excellent, sustained complete response rates.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Dobson</api:last-name><api:initials>LS</api:initials><api:first-names>LS</api:first-names><api:separate-first-names><api:first-name>L</api:first-name><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="18786" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/18786"/></api:links><api:last-name>Hancock</api:last-name><api:initials>BW</api:initials><api:first-names>BW</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>http://www.ncbi.nlm.nih.gov/pubmed/10789722</api:text></api:field><api:field name="c-goldoa" type="boolean" display-name="Gold Open Access?"><api:boolean>false</api:boolean></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1054/bjoc.2000.1176</api:text><api:links><api:link type="doi" href="http://doi.org/10.1054/bjoc.2000.1176"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1054/bjoc.2000.1176"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0007-0920</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>9</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Br J Cancer</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>Adult</api:keyword><api:keyword>Antineoplastic Combined Chemotherapy Protocols</api:keyword><api:keyword>Dactinomycin</api:keyword><api:keyword>Etoposide</api:keyword><api:keyword>Female</api:keyword><api:keyword>Humans</api:keyword><api:keyword>Methotrexate</api:keyword><api:keyword>Pregnancy</api:keyword><api:keyword>Retrospective Studies</api:keyword><api:keyword>Trophoblastic Neoplasms</api:keyword><api:keyword>Uterine Neoplasms</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="location" type="text" display-name="Country"><api:text>England</api:text></api:field><api:field name="online-publication-date" type="date" display-name="Online publication date"><api:date><api:day>4</api:day><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>1547</api:begin-page><api:end-page>1552</api:end-page></api:pagination></api:field><api:field name="pii" type="text" display-name="PII"><api:text>S0007092000911765</api:text></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>5</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>16</api:day><api:month>12</api:month><api:year>2016</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Original research article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>82</api:text></api:field></api:native></api:record><api:record format="native" id="2224667" source-id="13" source-name="crossref" source-display-name="Crossref" id-at-source="10.1054/bjoc.2000.1176" last-modified-when="2022-09-10T10:33:40.047+01:00"><api:native><api:field name="doi" type="text" display-name="DOI"><api:text>10.1054/bjoc.2000.1176</api:text><api:links><api:link type="doi" href="http://doi.org/10.1054/bjoc.2000.1176"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1054/bjoc.2000.1176"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1532-1827</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>9</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>British Journal of Cancer</api:text></api:field><api:field name="online-publication-date" type="date" display-name="Online publication date"><api:date><api:day>3</api:day><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>1547</api:begin-page><api:end-page>1552</api:end-page></api:pagination></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published online</api:text></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Springer Science and Business Media LLC</api:text></api:field><api:field name="publisher-url" type="text" display-name="Link 2"><api:text>http://dx.doi.org/10.1054/bjoc.2000.1176</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>11</api:day><api:month>4</api:month><api:year>2011</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>True</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>82</api:text></api:field></api:native></api:record><api:record format="native" id="3522573" source-id="7" source-name="scopus" source-display-name="Scopus" id-at-source="2-s2.0-0034090454" last-modified-when="2023-04-04T17:12:16.777+01:00"><api:citation-count>46</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>Persistent gestational trophoblastic disease is potentially fatal, but the majority of patients are cured with chemotherapy. Any developments in treatment are therefore being directed towards maintaining efficacy and reducing toxicity. We evaluated efficacy and toxicity of methotrexate, etoposide and dactinomycin (MEA) as first-line therapy for high risk disease and etoposide and dactinomycin (EA) as second-line therapy for methotrexate-refractory low risk disease in a retrospective analysis of 73 patients (38 MEA, 35 EA) treated since 1986 at a supra-regional centre. The median follow-up period was 5.5 years and the median number of cycles received was 7. The overall complete response rate was 85% (97% for EA, 75% for MEA). Of eight patients who failed to respond, four have since died and four were cured with platinum-based chemotherapy. Alopecia was universal. Grade II or worse nausea, emesis, or stomatitis was observed in 29%, 30% and 37% respectively. Fifty-one per cent experienced grade II/III anaemia, 8% grade II or higher thrombocytopenia and 64% grade III or IV neutropenia; in six cases this was complicated by sepsis. Fifty-four per cent of patients went on to have a normal pregnancy. No patient has developed a second malignancy. In conclusion, the MEA and EA chemotherapy regimens for persistent trophoblastic disease are very well tolerated, do not appear to affect future fertility and are associated with excellent, sustained complete response rates. (C) 2000 Cancer Research Campaign.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Dobson</api:last-name><api:initials>LS</api:initials><api:first-names>LS</api:first-names><api:separate-first-names><api:first-name>L</api:first-name><api:first-name>S</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">6701789003</api:identifier></api:identifiers></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">6604053967</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7403206142</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="18786" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/18786"/></api:links><api:last-name>Hancock</api:last-name><api:initials>BW</api:initials><api:first-names>BW</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>W</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">35109059400</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10789722</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0007-0920</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>9</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>British Journal of Cancer</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>1547</api:begin-page><api:end-page>1552</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>26</api:day><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Persistent gestational trophoblastic disease: Results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>82</api:text></api:field></api:native></api:record><api:record format="native" id="987" source-id="2" source-name="pubmed" source-display-name="PubMed" id-at-source="10789722" last-modified-when="2020-04-29T01:20:08.98+01:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>Persistent gestational trophoblastic disease is potentially fatal, but the majority of patients are cured with chemotherapy. Any developments in treatment are therefore being directed towards maintaining efficacy and reducing toxicity. We evaluated efficacy and toxicity of methotrexate, etoposide and dactinomycin (MEA) as first-line therapy for high risk disease and etoposide and dactinomycin (EA) as second-line therapy for methotrexate-refractory low risk disease in a retrospective analysis of 73 patients (38 MEA, 35 EA) treated since 1986 at a supra-regional centre. The median follow-up period was 5.5 years and the median number of cycles received was 7. The overall complete response rate was 85% (97% for EA, 75% for MEA). Of eight patients who failed to respond, four have since died and four were cured with platinum-based chemotherapy. Alopecia was universal. Grade II or worse nausea, emesis, or stomatitis was observed in 29%, 30% and 37% respectively. Fifty-one per cent experienced grade II/III anaemia, 8% grade II or higher thrombocytopenia and 64% grade III or IV neutropenia; in six cases this was complicated by sepsis. Fifty-four per cent of patients went on to have a normal pregnancy. No patient has developed a second malignancy. In conclusion, the MEA and EA chemotherapy regimens for persistent trophoblastic disease are very well tolerated, do not appear to affect future fertility and are associated with excellent, sustained complete response rates.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Dobson</api:last-name><api:initials>LS</api:initials><api:first-names>LS</api:first-names><api:separate-first-names><api:first-name>L</api:first-name><api:first-name>S</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">Gestational Trophoblastic Disease Centre, Weston Park Hospital, Sheffield, UK.</api:line></api:address></api:addresses></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="18786" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/18786"/></api:links><api:last-name>Hancock</api:last-name><api:initials>BW</api:initials><api:first-names>BW</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.ncbi.nlm.nih.gov/pubmed/10789722</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1054/bjoc.2000.1176</api:text><api:links><api:link type="doi" href="http://doi.org/10.1054/bjoc.2000.1176"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1054/bjoc.2000.1176"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pmc">PMC2363400</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0007-0920</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>9</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Br J Cancer</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Adult</api:keyword><api:keyword scheme="mesh">Antineoplastic Combined Chemotherapy Protocols</api:keyword><api:keyword scheme="mesh">Dactinomycin</api:keyword><api:keyword scheme="mesh">Etoposide</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Methotrexate</api:keyword><api:keyword scheme="mesh">Pregnancy</api:keyword><api:keyword scheme="mesh">Retrospective Studies</api:keyword><api:keyword scheme="mesh">Trophoblastic Neoplasms</api:keyword><api:keyword scheme="mesh">Uterine Neoplasms</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="location" type="text" display-name="Country"><api:text>England</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>1547</api:begin-page><api:end-page>1552</api:end-page></api:pagination></api:field><api:field name="pii" type="text" display-name="PII"><api:text>S0007092000911765</api:text></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>5</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-made-public-at-source-date" type="date" display-name="Record made publicly available"><api:date><api:day>12</api:day><api:month>5</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Comparative Study</api:item><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>82</api:text></api:field></api:native></api:record><api:record format="native" id="882194" source-id="18" source-name="epmc" source-display-name="Europe PubMed Central" id-at-source="MED:10789722" last-modified-when="2024-02-13T19:37:34.997+00:00"><api:citation-count>20</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>Persistent gestational trophoblastic disease is potentially fatal, but the majority of patients are cured with chemotherapy. Any developments in treatment are therefore being directed towards maintaining efficacy and reducing toxicity. We evaluated efficacy and toxicity of methotrexate, etoposide and dactinomycin (MEA) as first-line therapy for high risk disease and etoposide and dactinomycin (EA) as second-line therapy for methotrexate-refractory low risk disease in a retrospective analysis of 73 patients (38 MEA, 35 EA) treated since 1986 at a supra-regional centre. The median follow-up period was 5.5 years and the median number of cycles received was 7. The overall complete response rate was 85% (97% for EA, 75% for MEA). Of eight patients who failed to respond, four have since died and four were cured with platinum-based chemotherapy. Alopecia was universal. Grade II or worse nausea, emesis, or stomatitis was observed in 29%, 30% and 37% respectively. Fifty-one per cent experienced grade II/III anaemia, 8% grade II or higher thrombocytopenia and 64% grade III or IV neutropenia; in six cases this was complicated by sepsis. Fifty-four per cent of patients went on to have a normal pregnancy. No patient has developed a second malignancy. In conclusion, the MEA and EA chemotherapy regimens for persistent trophoblastic disease are very well tolerated, do not appear to affect future fertility and are associated with excellent, sustained complete response rates.</api:text></api:field><api:field name="addresses" type="address-list" display-name="Addresses"><api:addresses><api:address iso-country-code="GB"><api:line type="full">Gestational Trophoblastic Disease Centre, Weston Park Hospital, Sheffield, UK.</api:line></api:address></api:addresses></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Dobson</api:last-name><api:initials>LS</api:initials><api:first-names>LS</api:first-names><api:separate-first-names><api:first-name>L</api:first-name><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="orcid">0000-0002-8875-2164</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="18786" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/18786"/></api:links><api:last-name>Hancock</api:last-name><api:initials>BW</api:initials><api:first-names>BW</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1054/bjoc.2000.1176</api:text><api:links><api:link type="doi" href="http://doi.org/10.1054/bjoc.2000.1176"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1054/bjoc.2000.1176"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1532-1827</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10789722</api:identifier><api:identifier scheme="pmc">PMC2363400</api:identifier></api:identifiers></api:field><api:field name="is-open-access" type="boolean" display-name="Open access"><api:boolean>true</api:boolean></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0007-0920</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>9</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>British journal of cancer</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Trophoblastic Neoplasms</api:keyword><api:keyword scheme="mesh">Uterine Neoplasms</api:keyword><api:keyword scheme="mesh">Methotrexate</api:keyword><api:keyword scheme="mesh">Dactinomycin</api:keyword><api:keyword scheme="mesh">Etoposide</api:keyword><api:keyword scheme="mesh">Antineoplastic Combined Chemotherapy Protocols</api:keyword><api:keyword scheme="mesh">Retrospective Studies</api:keyword><api:keyword scheme="mesh">Pregnancy</api:keyword><api:keyword scheme="mesh">Adult</api:keyword><api:keyword scheme="mesh">Female</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="medium" type="text" display-name="Medium"><api:text>Print</api:text></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Open Access</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>1547</api:begin-page><api:end-page>1552</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>5</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="publisher-licence" type="text" display-name="Publisher licence"><api:text>CC BY</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>2</api:day><api:month>5</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Comparative Study</api:item><api:item>research-article</api:item><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>82</api:text></api:field><api:files><api:file proprietary-id="https://www.nature.com/articles/6691176.pdf"><api:file-url>https://www.nature.com/articles/6691176.pdf</api:file-url><api:extension>pdf</api:extension><api:is-open-access>true</api:is-open-access><api:file-version>Published version</api:file-version></api:file><api:file proprietary-id="https://europepmc.org/articles/PMC2363400?pdf=render"><api:file-url>https://europepmc.org/articles/PMC2363400?pdf=render</api:file-url><api:extension>pdf</api:extension><api:is-open-access>true</api:is-open-access><api:file-version>Published version</api:file-version></api:file></api:files></api:native></api:record><api:record format="native" id="2903638" source-id="10" source-name="dimensions" source-display-name="Dimensions" id-at-source="pub.1001255305" last-modified-when="2024-04-14T07:09:33.813+01:00"><api:citation-count>43</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Dobson</api:last-name><api:initials>LS</api:initials><api:first-names>LS</api:first-names><api:separate-first-names><api:first-name>L</api:first-name><api:first-name>S</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0654506120.51</api:identifier></api:identifiers></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01223762727.50</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.014331105607.96</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="18786" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/18786"/></api:links><api:last-name>Hancock</api:last-name><api:initials>BW</api:initials><api:first-names>BW</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>W</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01257257663.76</api:identifier></api:identifiers><api:author-types><api:author-type>corresponding</api:author-type></api:author-types></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1054/bjoc.2000.1176</api:text><api:links><api:link type="doi" href="http://doi.org/10.1054/bjoc.2000.1176"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1054/bjoc.2000.1176"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10789722</api:identifier><api:identifier scheme="pmc">PMC2363400</api:identifier></api:identifiers></api:field><api:field name="field-citation-ratio" type="decimal" display-name="Field citation ratio"><api:decimal>5.33</api:decimal></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0007-0920</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>9</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>British Journal of Cancer</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="for-2020">3215 Reproductive Medicine</api:keyword><api:keyword scheme="for-2020">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="rcdc">Hematology</api:keyword><api:keyword scheme="rcdc">Cancer</api:keyword><api:keyword scheme="rcdc">Genetics</api:keyword><api:keyword scheme="hrcs-rac">6 Evaluation of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-rac">6.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-hc">Cancer</api:keyword><api:keyword scheme="mesh">Adult</api:keyword><api:keyword scheme="mesh">Antineoplastic Combined Chemotherapy Protocols</api:keyword><api:keyword scheme="mesh">Dactinomycin</api:keyword><api:keyword scheme="mesh">Etoposide</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Methotrexate</api:keyword><api:keyword scheme="mesh">Pregnancy</api:keyword><api:keyword scheme="mesh">Retrospective Studies</api:keyword><api:keyword scheme="mesh">Trophoblastic Neoplasms</api:keyword><api:keyword scheme="mesh">Uterine Neoplasms</api:keyword></api:keywords></api:field><api:field name="online-publication-date" type="date" display-name="Online publication date"><api:date><api:day>4</api:day><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Hybrid OA</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>1547</api:begin-page><api:end-page>1552</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Springer Nature</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>31</api:day><api:month>8</api:month><api:year>2017</api:year></api:date></api:field><api:field name="relative-citation-ratio" type="decimal" display-name="Relative citation ratio"><api:decimal>1.12</api:decimal></api:field><api:field name="title" type="text" display-name="Title"><api:text>Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>82</api:text></api:field></api:native></api:record><api:record format="native" id="241502" source-id="11" source-name="wos-lite" source-display-name="Web of Science (Lite)" id-at-source="WOS:000086480600008" last-modified-when="2024-03-14T05:42:33.593+00:00"><api:citation-count>39</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Dobson</api:last-name><api:initials>LS</api:initials><api:first-names>LS</api:first-names><api:separate-first-names><api:first-name>L</api:first-name><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="researcherid">J-6898-2015</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="18786" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/18786"/></api:links><api:last-name>Hancock</api:last-name><api:initials>BW</api:initials><api:first-names>BW</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.webofscience.com/api/gateway?GWVersion=2&amp;SrcApp=sheffield_elements_live&amp;SrcAuth=WosAPI&amp;KeyUT=WOS:000086480600008&amp;DestLinkType=FullRecord&amp;DestApp=WOS_CPL</api:text></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="isidoc">304JT</api:identifier><api:identifier scheme="pubmed">10789722</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0007-0920</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>9</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>BRITISH JOURNAL OF CANCER</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>gestational trophoblastic disease</api:keyword><api:keyword>combination chemotherapy</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>1547</api:begin-page><api:end-page>1552</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>82</api:text></api:field></api:native></api:record><api:record format="native" id="24495" source-id="3" source-name="wos" source-display-name="Web of Science" id-at-source="WOS:000086480600008" last-modified-when="2014-07-25T11:06:51.24+01:00"><api:citation-count>13</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Dobson</api:last-name><api:initials>LS</api:initials><api:first-names>LS</api:first-names><api:separate-first-names><api:first-name>L</api:first-name><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="18786" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/18786"/></api:links><api:last-name>Hancock</api:last-name><api:initials>BW</api:initials><api:first-names>BW</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0007-0920</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>9</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>BRIT J CANCER</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>gestational trophoblastic disease</api:keyword><api:keyword>combination chemotherapy</api:keyword><api:keyword>PROGNOSTIC FACTORS</api:keyword><api:keyword>TUMORS</api:keyword><api:keyword>CYCLOPHOSPHAMIDE</api:keyword><api:keyword>VINCRISTINE</api:keyword><api:keyword>EXPERIENCE</api:keyword><api:keyword>EMA/CO</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>1547</api:begin-page><api:end-page>1552</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>5</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>82</api:text></api:field></api:native></api:record></api:records><api:fields/><api:all-labels type="keyword-list"><api:keywords><api:keyword origin="record-data" source="eprints">gestational trophoblastic disease</api:keyword><api:keyword origin="record-data" source="eprints">combination chemotherapy</api:keyword><api:keyword origin="record-data" source="manual">Adult</api:keyword><api:keyword origin="record-data" source="manual">Antineoplastic Combined Chemotherapy Protocols</api:keyword><api:keyword origin="record-data" source="manual">Dactinomycin</api:keyword><api:keyword origin="record-data" source="manual">Etoposide</api:keyword><api:keyword origin="record-data" source="manual">Female</api:keyword><api:keyword origin="record-data" source="manual">Humans</api:keyword><api:keyword origin="record-data" source="manual">Methotrexate</api:keyword><api:keyword origin="record-data" source="manual">Pregnancy</api:keyword><api:keyword origin="record-data" source="manual">Retrospective Studies</api:keyword><api:keyword origin="record-data" source="manual">Trophoblastic Neoplasms</api:keyword><api:keyword origin="record-data" source="manual">Uterine Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Adult</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Antineoplastic Combined Chemotherapy Protocols</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Dactinomycin</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Etoposide</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Methotrexate</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Pregnancy</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Retrospective Studies</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Trophoblastic Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Uterine Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Trophoblastic Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Uterine Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Methotrexate</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Dactinomycin</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Etoposide</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Antineoplastic Combined Chemotherapy Protocols</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Retrospective Studies</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Pregnancy</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Adult</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Female</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3215 Reproductive Medicine</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Hematology</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Genetics</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">6 Evaluation of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">6.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-hc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Adult</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Antineoplastic Combined Chemotherapy Protocols</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Dactinomycin</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Etoposide</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Methotrexate</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Pregnancy</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Retrospective Studies</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Trophoblastic Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Uterine Neoplasms</api:keyword><api:keyword origin="record-data" source="wos-lite">gestational trophoblastic disease</api:keyword><api:keyword origin="record-data" source="wos-lite">combination chemotherapy</api:keyword><api:keyword origin="record-data" source="wos">gestational trophoblastic disease</api:keyword><api:keyword origin="record-data" source="wos">combination chemotherapy</api:keyword><api:keyword origin="record-data" source="wos">PROGNOSTIC FACTORS</api:keyword><api:keyword origin="record-data" source="wos">TUMORS</api:keyword><api:keyword origin="record-data" source="wos">CYCLOPHOSPHAMIDE</api:keyword><api:keyword origin="record-data" source="wos">VINCRISTINE</api:keyword><api:keyword origin="record-data" source="wos">EXPERIENCE</api:keyword><api:keyword origin="record-data" source="wos">EMA/CO</api:keyword><api:keyword scheme="for" origin="issn-inferred">1112 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="for" origin="issn-inferred">1117 Public Health and Health Services</api:keyword><api:keyword scheme="science-metrix" origin="issn-inferred">Oncology &amp; Carcinogenesis</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3211 Oncology and carcinogenesis</api:keyword></api:keywords></api:all-labels><api:journal issn="0007-0920" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662" title="British Journal of Cancer"><api:records><api:record source-name="summary"><api:title>British Journal of Cancer</api:title></api:record></api:records></api:journal><api:relationships href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/987/relationships"/></api:object></api:result></api:response>